Enterome teams up with AbbVie to create molecular Dx for Crohn's disease

French startup Enterome Bioscience has been generating some upward momentum lately, inking deals and raking in funds to develop its personalized microbiome tests. Now, the company is teaming up with Big Pharma heavyweight AbbVie ($ABBV) to create molecular diagnostic tools that will help find the best therapies for patients with Crohn's disease. "This development partnership, along with the others that we have signed in recent months, demonstrates a strong and growing interest from a broad range of healthcare companies in our microbiome-based approach to disease monitoring and management," CEO Pierre Belichard said in a statement. Release (PDF)

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.